The case for treating tobacco dependence as a chronic disease
- PMID: 18378950
- DOI: 10.7326/0003-4819-148-7-200804010-00012
The case for treating tobacco dependence as a chronic disease
Abstract
Smoking remains the leading cause of preventable death in the United States, yet it is still regarded by many as merely a bad habit. Most smokers want to quit but find it difficult. Behavioral counseling and pharmacotherapies are available, safe, and effective in the treatment of tobacco dependence. Nicotine replacement therapy effectively delivers nicotine in safer doses without exposure to the toxins and chemicals in cigarette smoke. The optimal duration of tobacco dependence treatment is unknown, and some smokers may require extended courses. For smokers using long-term cessation medications, health care providers should encourage treatment and insurance carriers should cover it. Both tobacco dependence and such conditions as diabetes are similar in their potential to exacerbate other diseases, their behavioral components of treatment, and their effectiveness of medications. Despite these similarities, treatments for diabetes are well covered by insurance, whereas tobacco dependence treatments are often limited. Tobacco dependence should share the status of other chronic illnesses, with effective treatments given as long as is necessary to achieve successful clinical outcomes.
Comment in
-
Is long-term use of antismoking drugs consistent with public health goals or pharmaceutical marketing goals?Ann Intern Med. 2008 Dec 2;149(11):838; author reply 838. doi: 10.7326/0003-4819-149-11-200812020-00016. Ann Intern Med. 2008. PMID: 19047036 No abstract available.
Similar articles
-
Treatment of nicotine dependence.Am J Health Syst Pharm. 1995 Feb 1;52(3):265-81; quiz 314-5. doi: 10.1093/ajhp/52.3.265. Am J Health Syst Pharm. 1995. PMID: 7749954 Review.
-
[Smoking reduction and temporary abstinence: new approaches for smoking cessation].J Mal Vasc. 2003 Dec;28(5):293-300. J Mal Vasc. 2003. PMID: 14978435 Review. French.
-
Smoking cessation for patients with cardiovascular disease: what is the best approach?Am J Cardiovasc Drugs. 2003;3(5):339-49. doi: 10.2165/00129784-200303050-00005. Am J Cardiovasc Drugs. 2003. PMID: 14728068 Review.
-
Managing tobacco use: the neglected cardiovascular disease risk factor.Eur Heart J. 2013 Nov;34(42):3259-67. doi: 10.1093/eurheartj/eht352. Epub 2013 Sep 7. Eur Heart J. 2013. PMID: 24014389 Review.
-
Concurrent E-Cigarette Use During Tobacco Dependence Treatment in Primary Care Settings: Association With Smoking Cessation at Three and Six Months.Nicotine Tob Res. 2017 Feb;19(2):183-189. doi: 10.1093/ntr/ntw218. Epub 2016 Aug 31. Nicotine Tob Res. 2017. PMID: 27613911
Cited by
-
Smoking trends in the Nurses' Health Study (1976-2003).Nurs Res. 2008 Nov-Dec;57(6):374-82. doi: 10.1097/NNR.0b013e31818bf38b. Nurs Res. 2008. PMID: 19018212 Free PMC article.
-
Recruiting and engaging smokers in treatment in a primary care setting: developing a chronic care model implemented through a modified electronic health record.Transl Behav Med. 2013 Sep;3(3):253-63. doi: 10.1007/s13142-012-0178-8. Transl Behav Med. 2013. PMID: 24073176 Free PMC article.
-
Comparative effectiveness of post-discharge strategies for hospitalized smokers: Study protocol for the Helping HAND 4 randomized controlled trial.Trials. 2020 Apr 16;21(1):336. doi: 10.1186/s13063-020-04257-7. Trials. 2020. PMID: 32299470 Free PMC article.
-
Seven-day continuous abstinence rate from smoking at 1, 2, or 3 years after the use of varenicline.Tuberc Respir Dis (Seoul). 2015 Apr;78(2):92-8. doi: 10.4046/trd.2015.78.2.92. Epub 2015 Apr 2. Tuberc Respir Dis (Seoul). 2015. PMID: 25861342 Free PMC article.
-
Parent eReferral to Tobacco Quitline: A Pragmatic Randomized Trial in Pediatric Primary Care.Am J Prev Med. 2019 Jul;57(1):32-40. doi: 10.1016/j.amepre.2019.03.005. Epub 2019 May 21. Am J Prev Med. 2019. PMID: 31122792 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials